News Digest / Ticker: APRE

Ticker: APRE

10:40am, Thursday, Jan 29, 2026

Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint

Aprea Therapeutics (NASDAQ:APRE) stock dropped nearly 20% following early-stage trial data for APR-1051, highlighting mixed outcomes and cautious investor reaction.

09:10am, Tuesday, Aug 12, 2025

Aprea advances two Phase 1 cancer programs but faces cash crunch, runway into Q1 2026

09:03am, Wednesday, May 14, 2025

Aprea Therapeutics Faces Financial Challenges Amid Clinical Progress and Funding Needs in Q1 2025